Elevate your patient’s experience

Prescribe proven protection with a first and only for Ig—Hizentra Prefilled Syringes

Prescribe 10g Hizentra Prefilled Syringes

Proven Efficacy and Safety in PI

#1 Ig Prescribed for PI

Choose Hizentra—the SCIg with the longest record of proven efficacy and safety in PI

Hizentra is the only SCIg with proven experience since 2010
and over 9.3 million exposures worldwide4

Based on grams of Hizentra sold worldwide from 2010 through September 2020.


The US Phase 3 Trial confirmed the efficacy and tolerability of Hizentra, indicated in patients age 2 and older6*

US Phase 3 Trial Results (1 year)6†

ZERO

Serious bacterial infections

(per subject year, annualized rate)

2.76

Any infections

(per subject year, annualized rate)

ZERO

Serious adverse reactions

Two subjects withdrew from the study due to adverse reactions.

*Demonstrated in patients 5–72 years of age in the 12-month US phase 3 trial with Hizentra weekly (n=38).
Hizentra was initiated at a weekly dose of 153% of the previous weekly-equivalent IVIg dose in the US study.
Serious bacterial infections were defined as bacterial pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.

See US Phase 3 Trial and US Extension Study Designs

US Phase 3 Trial

A prospective, open-label, multicenter, single-arm, clinical study conducted in the U.S. evaluated the efficacy, tolerability, and safety of Hizentra in 49 adult and pediatric subjects with PI. Subjects previously receiving monthly treatment with IVIg were switched to weekly subcutaneous administration of Hizentra.

US Extension Study

Phase 3, prospective, open-label, single-arm extension study in 21 patients with PI who had previously been treated with Hizentra in pivotal studies.

A long-term extension study (1.7 years) demonstrated safe, sustained,
effective protection from infections
7

US Extension Study Results (1.7 years)7

0.06§

Serious bacterial infections||

(per subject year, annualized rate)

2.38

Any infections

(per subject year, annualized rate)

ZERO

Treatment-related serious adverse events

Zero subjects discontinued because of treatment-related adverse events.

§During the US extension study, 2 SBIs (bacterial pneumonia) in 2 subjects were reported, giving an annualized rate of 0.06 infections per subject (n=21).
||Serious bacterial infections were defined as bacterial pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.
Frequently asked questions about Hizentra for PI

Want to know more about Hizentra? See the answers to prescribers’ frequently asked questions.

Frequently asked questions about PI
Flexibility with Hizentra for self-administration for PI

Create personalized treatment plans to meet each patient's clinical needs and personal preferences.

See why Hizentra might be right for your patients
acuity
You are now leaving the current website.

Do you want to continue?

No Yes